US 11,806,385 B2
Biomarkers for monitoring immune transformation
Howard E. Gendelman, Omaha, NE (US); R. Lee Mosley, Omaha, NE (US); Gary Siuzdak, La Jolla, CA (US); and Erica Forsberg, San Diego, CA (US)
Assigned to BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA, Lincoln, NE (US); and THE SCRIPPS RESEARCH INSTITUTE, Jolla, CA (US)
Appl. No. 16/092,561
Filed by Board of Regents of the University of Nebraska, Lincoln, NE (US); and The Scripps Research Institute, La Jolla, CA (US)
PCT Filed Apr. 24, 2017, PCT No. PCT/US2017/029111
§ 371(c)(1), (2) Date Oct. 10, 2018,
PCT Pub. No. WO2017/185085, PCT Pub. Date Oct. 26, 2017.
Claims priority of provisional application 62/326,062, filed on Apr. 22, 2016.
Prior Publication US 2019/0117735 A1, Apr. 25, 2019
Int. Cl. G01N 33/50 (2006.01); A61K 38/19 (2006.01); A61K 38/22 (2006.01); G01N 33/68 (2006.01); G01N 33/94 (2006.01)
CPC A61K 38/193 (2013.01) [A61K 38/2278 (2013.01); G01N 33/505 (2013.01); G01N 33/6896 (2013.01); G01N 33/942 (2013.01); G01N 2800/52 (2013.01)] 4 Claims
 
1. A method of determining the efficacy of a Parkinson's disease treatment, said method comprising:
a) administering the Parkinson's disease treatment to a subject having Parkinson's disease, wherein said Parkinson's disease treatment is sargramostim; and
b) measuring the amount of at least one metabolite of the tryptophan pathway in a biological sample obtained from the subject after step a),
wherein at least one of the metabolites measured in step b) is L-kynurenine, quinolinic acid, or serotonin, and
wherein an increase in the amount of L-kynurenine or quinolinic acid after administration of the Parkinson's disease treatment indicates the Parkinson's disease treatment is effective against Parkinson's disease or wherein a decrease in the amount of serotonin after administration of the Parkinson's disease treatment indicates the Parkinson's disease treatment is effective against Parkinson's disease; and
c) treating said subject with sargramostim when the Parkinson's disease treatment is effective against Parkinson's disease.